|
[1]
|
Network NCC. Non-Small Cell Lung Cancer (Version 7.2021).
https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
|
|
[2]
|
The Nobel Prize in Physiology or Medicine 2018 [Press Release] Stockholm: The Nobel Assembly at Karolinska Institutet 2018 (2018). https://www.nobelprize.org/prizes/medicine/2018/press-release
|
|
[3]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpointsin Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264.
[Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 1627-1639.
[Google Scholar] [CrossRef]
|
|
[5]
|
Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135.
[Google Scholar] [CrossRef]
|
|
[6]
|
Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Perez-Gracia, J.L., Han, J.Y., et al. (2016) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550.
[Google Scholar] [CrossRef]
|
|
[7]
|
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., et al. (2017) Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multcentre Randomised Controlled Trial. The Lancet, 389, 255-265.
[Google Scholar] [CrossRef]
|
|
[8]
|
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833.
[Google Scholar] [CrossRef]
|
|
[9]
|
Paz-Ares, L., Ciuleanu, T.E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., et al. (2021) First-Line Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (Checkmate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211.
[Google Scholar] [CrossRef]
|
|
[10]
|
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., et al. (2021) Five-Year Outcomes with Pembrolizumab versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score >/= 50. Journal of Clinical Oncology, 39, 2339-2349.
[Google Scholar] [CrossRef]
|
|
[11]
|
Borghaei, H., Gettinger, S., Vokes, E.E., Chow, L.Q.M., Burgio, M.A., de Castro Carpeno, J., et al. (2021) Five-Year Outcomes from the Randomized, Phase III Trials Checkmate 017 and 057: Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 39, 723-733.
[Google Scholar] [CrossRef]
|
|
[12]
|
Felip, E., Altorki, N., Zhou, C., Csoszi, T., Vynnychenko, I., Goloborodko, O., et al. (2021) Adjuvant Atezolizumab after Adjuvant Chemotherapy in Resected Stage IBIIIA Non-Small-Cell Lung Cancer (Impower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial. The Lancet, 398, 1344-1357.
[Google Scholar] [CrossRef]
|
|
[13]
|
Horn, L., Mansfield, A.S., Szczesna, A., Havel, L., Krzakowski, M., Hochmair, M.J., et al. (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer. The New England Journal of Medicine, 379, 2220-2229.
[Google Scholar] [CrossRef]
|
|
[14]
|
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., et al. (2019) Durvalumab plus Platinum- Etoposide versus Platinum-Etoposide in First Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial. The Lancet, 394, 1929-1939.
|
|
[15]
|
Peters, S., Pujol, J.L., Dafni, U., Domine, M., Popat, S., Reck, M., et al. (2021) Consolidation Nivolumab and Ipilimumab versus Observation in Limited-Disease Small Cell Lung Cancer after Chemo-Radiotherapy—Results from the Randomised Phase II ETOP/IFCT 4-12 Stimuli Trial. Annals of Oncology, 33, 67-79.
|
|
[16]
|
Camidge, D.R., Doebele, R.C. and Kerr, K.M. (2019) Comparing and Contrasting Predictive Biomarkers for Immunotherapy and Targeted Therapy of NSCLC. Nature Reviews Clinical Oncology, 16, 341-355.
[Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Suresh, K., Naidoo, J., Lin, C.T. and Danoff, S. (2018) Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest, 154, 1416-1423.
[Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 2018-2028.
[Google Scholar] [CrossRef]
|
|
[19]
|
Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., et al. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 378, 2078-2092.
[Google Scholar] [CrossRef]
|
|
[20]
|
Nosaki, K., Saka, H., Hosomi, Y., Baas, P., de Castro, G., Reck, M., et al. (2019) Safety and Efficacy of Pembrolizumab Monotherapy in Elderly Patients with PD-L1-Positive Advanced Non-Small-Cell Lung Cancer: Pooled Analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 Studies. Lung Cancer, 135, 188-195.
[Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., et al. (2016) Atezolizumab versus Docetaxel for Patients with Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open- Label, Phase 2 Randomised Controlled Trial. The Lancet, 387, 1837-1846.
[Google Scholar] [CrossRef]
|
|
[22]
|
Carbone, D.P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., et al. (2017) First Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 376, 2415-2426.
[Google Scholar] [CrossRef]
|
|
[23]
|
Paz-Ares, L., Spira, A., Raben, D., Planchard, D., Cho, B.C., Ozguroglu, M., et al. (2020) Outcomes with Durvalumab by Tumour PD-L1 Expression in Unresectable, Stage III Non-Small-Cell Lung Cancer in the PACIFIC Trial. Annals of Oncology, 31, 798-806.
[Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.W., Carcereny Costa, E., et al. (2019) Nivolumab plus Ipilimumab in Advanced Non Small-Cell Lung Cancer. The New England Journal of Medicine, 381, 2020- 2031.
[Google Scholar] [CrossRef]
|
|
[25]
|
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., et al. (2020) Association of Tumour Mutational Burden with Outcomes in Patients with Advanced Solid Tumours Treated with Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study. The Lancet Oncology, 21, 1353-1365.
[Google Scholar] [CrossRef]
|
|
[26]
|
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., et al. (2018) Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients with Non-Small-Cell Lung Cancer Profiled with Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 36, 633-641.
[Google Scholar] [CrossRef]
|
|
[27]
|
Liu, S.V., Reck, M., Mansfield, A.S., Mok, T., Scherpereel, A., Reinmuth, N., et al. (2021) Updated Overall Survival and PD-L1 Subgroup Analysis of Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Atezolizumab, Carboplatin, and Etoposide (Impower133). Journal of Clinical Oncology, 39, 619-630.
[Google Scholar] [CrossRef]
|
|
[28]
|
Rudin, C.M., Awad, M.M., Navarro, A., Gottfried, M., Peters, S., Csoszi, T., et al. (2020) Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double- Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology, 38, 2369-2379.
[Google Scholar] [CrossRef]
|
|
[29]
|
Torralvo, J., Friedlaender, A., Achard, V. and Addeo, A. (2019) The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-Small Cell Lung Cancer: A Single Centre Experience. Cancer Genomics Proteomics, 16, 577-582.
[Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Skoulidis, F., Goldberg, M.E., Greenawalt, D.M., Hellmann, M.D., Awad, M.M., Gainor, J.F., et al. (2018) STK11/L- KB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 8, 822-835.
|
|
[31]
|
Shire, N.J., Klein, A.B., Golozar, A., Collins, J.M., Fraeman, K.H., Nordstrom, B.L., et al. (2020) STK11 (LKB1) Mutations in Metastatic NSCLC: Prognostic Value in the Real World. PLOS ONE, 15, e0238358.
[Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Gainor, J.F., Shaw, A.T., Sequist, L.V., Fu, X., Azzoli, C.G., Piotrowska, Z., et al. (2016) EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clinical Cancer Research, 22, 4585-4593.
[Google Scholar] [CrossRef]
|
|
[33]
|
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., et al. (2019) Immune Checkpoint Inhibitors for Patients with Advanced Lung Cancer and Oncogenic Driver Alterations: Results from the Immunotarget Registry. Annals of Oncology, 30, 1321-1328.
[Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Garassino, M.C., Cho, B.C., Kim, J.H., Mazieres, J., Vansteenkiste, J., Lena, H., et al. (2018) Durvalumab as Third-Line or Later Treatment for Advanced Non-Small Cell Lung Cancer (Atlantic): An Open-Label, Single-Arm, Phase 2 Study. The Lancet Oncology, 19, 521-536.
|
|
[35]
|
Lee, C.K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., et al. (2018) Clinical and Molecular Characteristics Associated with Survival among Patients Treated with Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. JAMA Oncology, 4, 210-216.
[Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Mamdani, H., Ahmed, S., Armstrong, S., Mok, T. and Jalal, S.I. (2017) Blood-Based Tumor Biomarkers in Lung Cancer for Detection and Treatment. Translational Lung Cancer Research, 6, 648-660.
[Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Thompson, J.C., Carpenter, E.L., Silva, B.A., Rosenstein, J., Chien, A.L., Quinn, K., et al. (2021) Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients with Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precision Oncology, 5, 510-524.
[Google Scholar] [CrossRef]
|